528 results about "Ferritin" patented technology

The invention discloses a novel coronavirus S protein double-region subunit nano vaccine based on pyrococcus furiosus ferritin. The virus receptor binding domain (RBD) and fusion peptide (FP) are usedtogether as a double antigen, and are connected with pyrococcus furiosus ferritin (PF_Ferritin) to from a fusion protein RBD-FP-PF_Ferritin to realize antigen multimerization; and then an eukaryoticcell expression system is used for expressing, and a 24-mer nano antigen can be formed through self-assembly of PF_Ferritin. The scheme can overcome the shortcoming of insufficient immunogenicity of RBD monomers, the obtained vaccine can significantly increase the level of a neutralizing antibody against the virus of a host, and the produced antibody has the ability to strongly block the virus from invading target cells. In addition, the vaccine of the invention is simple in preparation method, is easy to purify, and is high in safety, and the vaccine can be relatively quickly applied to clinical trials.

The present invention relates to an ultrapure human transferrin, and to methods for manufacturing the ultrapure transferrin. The transferrin may be holo-, apo- or at any desired degree of iron saturation. The invention further relates to the use of ultrapure transferrin as the protein moiety of conjugates, and to pharmaceutical compositions comprising ultra transferrin alone as well as in the form of a conjugate.

Provided is a compound semiconductor nanoparticle that exhibits circularly polarized luminescence characteristics. CdS prepared inside a core of ferritin, which is a cage-like protein, exhibits a high circularly polarized luminescence (CPL). A wavelength of the circularly polarized luminescence (CPL) can be controlled by laser irradiation, thereby enabling utilization of the compound semiconductor nanoparticle in the field of bionanotechnology, for example, in creating a WORM (Write-Once Read-Many times) memory. As the cage-like protein, which is a protein with a cavity formed therein, a protein belonging to the ferritin protein family, such as apoferritin, or a recombinant thereof can be used.

The invention relates to the field of immunomedicine, in particular to an SARS-CoV-2 RBD conjugated nanoparticle vaccine. The vaccine comprises an immunogenic compound, and the immunogenic compound comprises: a) a nanoparticle carrier obtained by self-assembly with a vector protein subjected to fusion expression with SpyCatcher; and b) an RBD antigen of the SARS-CoV-2 virus, which is subjected tofusion expression with SpyTag, the vector protein is selected from Ferritin, mi3 and I53-50, and the vector protein and the antigen are in covalent linkage through SpyCatcher-SpyTag.

The present invention relates to devices and methods for the detection of occult blood in a test sample. These devices and methods can detect the presence of one or more of the following components of occult blood: hemoglobin, transferrin, hemoglobin-haptoglobin complex, and albumin. Methods for the detection of occult blood in a test sample include the following steps: exposing said test sample to two or more of the following antibodies: anti-hemoglobin antibodies, anti-hemoglobin-haptoglobin-complex antibodies, anti-transferrin antibodies, and anti-albumin antibodies or one or more of the following antibodies: anti-hemoglobin-haptoglobin-complex antibodies, anti-transferrin antibodies, and anti-albumin antibodies; determining the level of reactions between the antibodies and their corresponding components of occult blood that may be in the test sample; and deciding on the presence of occult blood. The devices of this invention can have two or more of test areas containing two or more of the following antibodies: anti-hemoglobin antibodies, anti-transferrin antibodies, anti-hemoglobin-haptoglobin complex antibodies, and anti-albumin antibodies or one or more of test areas containing one or more of the following antibodies: anti-transferrin antibodies, anti-hemoglobin-haptoglobin complex antibodies, and, anti-albumin antibodies. The devices and methods of this invention are simple and produce rapid responses.

The invention provides a health-care food for improving nutritional anemia, which is prepared from (by weight ratio) spirulina azurin 1-50%, matrimony vine extract 5-80%, ferrous lactate 1-60%, the preparation of the food comprises the steps of raw material preparation, batching, capsule filling, capsule polishing, bottling, examining, boxing, warehouse-in.

Use of lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof and at least one anti-tumour food factor selected from soy protein and vitamin D inhibits tumour formation or growth, maintains or improves one or both of the white blood cell count and red blood cell count, stimulates the immune system, and / or treats or prevents cancer. Dietary (foods or food supplements), nutraceutical or pharmaceutical compositions may be used.

The present invention provides an antineoplastic drug with ferritin as a carrier and a preparation method thereof, the method comprising the following steps: preparing ferritin; performing high pressure treatment on a mixed solution of ferritin and antineoplastic drug at a pressure of 200-800MPa6 ‑20h; the product after high pressure treatment is separated and purified to obtain an anti-tumor drug with ferritin as a carrier. The method of the present invention can not only increase the loading ratio of drugs, the yield of drug-loaded ferritin is close to 100%, but also can completely recover free unloaded anti-tumor drugs, improve production efficiency, reduce production costs, and is suitable for large-scale industrial production .

A material for removing oxo-anions and metal cations from a liquid. This material is characterized in that it comprises hyperthermophilic ferritin. The present invention also relates to a method for removing at least one of oxo-anions and metal cations from a liquid. This method is characterized in that a material comprising hyperthermophilic ferritin is used as filter material. It is especially preferred that said liquid is comprised of water. The invention also relates to the use of hyperthermophilic ferritin for removing metal cations and oxo-anions from a liquid.

This invention uses placental alkaline phosphatase (“PALP”), and other members of the alkaline phosphatase family, to reduce the death and thereby maintain or enhance the viability and function of insulin-producing islet β-cells including insulin secretion. PALP may be administered to a patient that has received transplanted islet cells to protect the transplanted islets against ROS-mediated attacks by the patient's immune system. Transferrin and other promoters of islet survival may also be used to enhance the effects of PALP on islet viability both in vivo and in vitro.

The invention relates to a lactoferrin antibacterial peptide, the preparation method and the application thereof. The method utilizes the lactoferrin and the enzyme preparation in bovine colostrum to prepare the lactoferrin antibacterial peptide zymolyte through enzymic hydrolysis, and subjects the zymolyte to macroporous absorption static or dynamic desalination, gel filtration chromatography, half-preparation high efficiency liquid chromatography and analysis-type high efficiency liquid chromatography for separation and purification to obtain a pure lactoferrin antibacterial peptide product. The product has high-efficient and broad-spectrum antibacterial capability, thereby having broad prospects for application in food, feed and medical fields.

This invention concerns a method of making an anti-infective composition for oral administration using an agent selected from the group consisting of lactoferrin protein and lysozyme protein. The method comprises three steps. The nucleic acid, which encodes a lactoferrin or lysozyme protein, is expressed in a monocot seed. The protein is isolated from the seed. This protein isolation compromises greater than 3% of the total soluble protein in the monocot seed. The protein is then formulated for oral administration.

The invention discloses a Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine. According to the Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine, a virus receptor binding domain (RBD) is used as an antigen and is connected with a helicobacter pylori polymer protein (HP _ Ferritin) to form a fusion protein RBD-HP_ Ferritin, so that antigen multimerization is realized; and expressing by using an eukaryotic cell expression system is carried out, so as to form a 24-polymer nano antigen through the self-assembly action of HP _ Ferritin. According to the scheme, the defect that RBD monomers are insufficient in immunogenicity can be overcome, the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses, and the generated antibodies have the capacity of strongly preventing the viruses from invading target cells. Moreover, the vaccine is simple in preparation method, easy to purify and high in safety, and can be quickly applied to clinical tests.

An iron-protein hydrolysate complex which may be used to fortify foods and beverages with iron. The complex is formed of ferrous ions chelated to partially hydrolyzed egg white protein. The hydrolyzed egg white protein has a molecular weight in the range of about 500 to about 10,000. The complexes are sufficiently stable as to be suitable for use in sterilized products, such as retorted products. Moreover, despite the stability, the iron in the complexes has substantially the same bioavailability as ferrous sulfate.

A fusion polypeptide, including a first polypeptide fragment including 5 to 30 amino acids, the first polypetide fragment is fused between a first amino acid and a fifth amino acid of a fourth loop of a human-derived ferritin monomer.

The present invention relates to an infant formula milk powder capable of preventing and alleviating infant iron deficiency anemia and a preparation method thereof. The formula milk powder comprises components such as vegetable oil, fresh milk, whey powder, lactose powder, whey protein powder, oligosaccharides, complex vitamins and complex minerals, wherein the lactoferrin and vitamin C, or alternatively, an iron source (calculated as iron), lactoferrin and vitamin C are maintained in the appropriate mass ratios, and the formula milk powder of the present invention is obtained by performing mixing, homogenizing, cooling, concentrating and spray-drying, packaging or directly using a step-by-step mixing method. The formula milk powder comprises appropriate amounts of vitamin C and lactoferrin, as well as an appropriate amount of iron source as further provided, and the three are combined according to an appropriate proportion, so that the combination of the three kinds of the substances have a synergistic effect, and the absorption and utilization rate of iron are increased dramatically, thereby not only achieving the desirable iron supplementation effect, but also preventing and alleviating the phenomenon of infant iron deficiency anemia.

The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided.

The invention discloses a tumor targeting metal complex, a synthetic method and application. The synthetic method comprises the steps of connecting a ligand with a substituent group and a targeting molecule, complexing the ligand and metal ions, and synthesizing to obtain the tumor targeting metal complex, wherein the ligand is one of a phenanthroline derivative, a dipyridyl derivative, a benzimidazole derivative, a phenyl-pyridine derivative and a thiophene-pyridine derivative; the targeting molecule is one of biotin, folic acid, integrin, transferrin, cell-penetrating peptide, octa-poly-L-arginine, MUC-1 attached membrane protein, galactosamine, neovascular targeting peptide and a granulocyte-macrophage colony-stimulating factor; the metal ions are ruthenium, osmium, rhodium or iridium ions. The complex obtained by the method provided by the invention can be selectively absorbed by tumor cells, and induces apoptosis of the tumor cells. In a nude mouse tumor-bearing model, the tumor targeting metal complex can image and treat tumors, and the toxicity of organs and tissues is reduced.

The present invention involves the discovery that various liquid (whey) streams drained or expelled from cheese curd after salt addition in the preparation of cheese contain enriched levels of bioactive proteins such as lactoferrin, lactoperoxidase, immunoglobulins, and growth factors. According to the invention, these proteins may be further enriched through manipulation of the cheese salting process as described herein. The methods of the invention may be used to produce various whey products with enriched levels of all the above bioactive proteins present and, through manipulation of salting conditions, to enrich these proteins selectively.

The invention discloses a tumor homing cell-penetrating peptide tLyP-1 modified apoferritin nano-cage and a preparation method thereof. The protein nano-cage is hollow cage-shaped protein formed by self-assembling 24 protein subunits; and one tumor homing cell-penetrating peptide tLyP-1 is modified on an N end of each protein subunit by utilizing a gene recombination technology to obtain a recombinant human body heavy-chain ferritin nano-cage with a tLyP-1 modified surface. According to the protein nano-cage provided by the invention, a medicine is loaded into the nano-cage through adjusting depolymerization and recombination of the protein subunits; the nano-cage has good water solubility and biocompatibility, has excellent stability in a human body and has a uniform size; the nano-cage can be specifically combined with a lot of neuropilin receptors 1 (NRP-1) which are expressed in tumor neovascularization and tumor cells of malignant tumors including gliomas, breast cancer, pancreatic cancer, gastric cancer, colorectal cancer, non-small cell lung cancer and the like; and types of the tumors treated by the nano-cage are greatly increased and the targeting ability of tumor treatment is improved. The protein nano-cage provided by the invention has an extremely great application prospect in the aspects of tumor diagnosis and treatment and the like.

The invention discloses an African swine fever vaccine and a preparation method thereof. According to the invention, the structural proteins P72, P30, P54 or CD2v-AC of the African swine fever virus are respectively displayed on the surface of the cage-shaped structure of the self-assembled ferritin, so that the humoral immune efficacy and width of the vaccine are improved, and the immunogenicity of the structural proteins of the African swine fever virus is improved. Structural proteins P30, P54 and CD2v are recombined to obtain recombinant proteins, and the recombinant proteins are connected with ubiquitin to obtain two recombinant proteins, so that the cellular immune effect of the structural proteins of the African swine fever virus is further improved, and better immune protection is provided for animals. The invention also provides a method for preparing the recombinant protein or the African swine fever vaccine. The African swine fever vaccine provided by the invention can initiate a wide neutralizing anti-African swine fever antibody, not only improves the immune efficacy, but also expands the immune range, provides effective immune protection for virulent infection, and has the potential of becoming a universal safe vaccine with multiple protection effects.

The invention discloses a biotinylation bovine serum albumin and streptavidin enzyme-labeled reaction plate and a preparation method thereof, belonging to the field of labeling immunoassay in laboratory medicine. The reaction plate comprises a polystyrene enzyme-labeled plate; each micropore is respectively coated with the biotinylation bovine serum albumin and the streptavidin; and a biotinylation antibody is stored in a liquid phase to serve as a reaction reagent for later use. When in detection, the biotinylation antibody and an antigen to be detected are simultaneously added on the enzyme-labeled reaction plate; the biotinylation antibody and the antigen to be detected are simultaneously reacted; and biotin molecules and the streptavidin are combined and fixed on the surface of solid phase materials. According to the invention, the antigen to be detected and the biotinylation antibody are placed in the liquid phase so as to improve reaction rate, widen detection range of ferritin, and reduce hook effects in double antibody sandwich experiment. Indexes such as reaction sensitivity, accuracy, precision and the like of the enzyme label satisfy the technical requirements; the usage ratio of the coated antibody is improved; the usage amount of the antibody is reduced; and the cost of a reagent box is greatly reduced.

The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.

The invention discloses a helicobacter pylori ferritin-based novel coronavirus S protein double-region subunit nanovaccine. According to the invention, a receptor binding domain (RBD) of a virus and afusion peptide (FP) are jointly used as double antigens, and the double antigens are connected with a helicobacter pylori polymer protein (HP _ Ferritin) to form a fusion protein RBD-FP-HP _ Ferritin, so that antigen multimerization is realized; and then an eukaryotic cell expression system is utilized for expression, so as to form a 24-polymer nano antigen through the self-assembly action of HP_ Ferritin. According to the scheme, the defect that RBD monomers are insufficient in immunogenicity can be overcome, the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses, and the generated antibodies have the capacity of strongly preventing the viruses from invading target cells. Moreover, the vaccine is simple in preparation method, easy to purifyand high in safety, and can be quickly applied to clinical tests.

The invention relates to a culture medium and the usage thereof, in particular to the Chinese hamster ovary cell enlarging culture medium and the usage thereof. The invention belongs to the biological product field. The Chinese hamster ovary cell enlarging non-protein culture medium of the invention, wherein comprises minimal medium, and also comprises microelement, Transferrin and Insulin subsistent. A serum-containing routine culture medium can be directly replaced with the serum free culture medium of the Chinese hamster ovary cells, and the Chinese hamster ovary cells are not required to adapt process.

The invention provides a bionic binary cooperative nano-carrier as well as a preparation method and an application thereof. The bionic binary cooperative nano-carrier comprises an erythrocyte membrane, glucose oxidase, iron-supporting ferritin nano-particles and a photosensitizer, wherein the glucose oxidase and the iron-supporting ferritin nano-particles are coated with the erythrocyte membrane,and the photosensitizer is embedded into the surface of the erythrocyte membrane or entrapped by the erythrocyte membrane. Chain stimulative responsibility coordination of tumor hunger therapy and chemical kinetic therapy is realized, two enzymes are conveyed to a target site of an organism with the carrier on the basis of biocompatibility of the erythrocyte membrane and tumor targeting of targeting molecules, accurate administration is realized by membrane rupture based on 808 nm near-infrared light illumination in the tumors, the problem of drug resistance is solved effectively, furthermore,systemic toxicity caused by drug application is remarkably reduced, and damage to other normal tissue in an in-vivo circulation process is prevented effectively. The invention further provides the preparation method of the bionic binary cooperative nano-carrier. The bionic binary cooperative nano-carrier and the preparation method have good application prospect.

The invention provides a purification method for recombination human lactoferrin, animal lactoferrin and lactoperoxidase. The method comprises: taking a milk sample containing recombination human lactoferrin as a raw material, pre-treating to obtain degreased milk, performing cation exchange chromatographic separation on the obtained degreased milk, then under different salt concentration conditions, performing elution separation on lactoferrin and lactoperoxidase, so as to obtain high-purity lactoferrin and lactoperoxidase, and further performing separation on the solution rich in lactoferrin by utilizing hydrophobic interaction chromatography to respectively obtain recombination human lactoferrin and animal source lactoferrin both with the purity of 99% or more. The purity of recombination human lactoferrin obtained by utilizing the purification method provided by the invention is 99% or more, and also recombination human lactoferrin has the physical and chemical activities and physiological functions all similar to those of natural human lactoferrin; and the technology is a one-step purification process, so that the purification method is low in cost, simple and suitable for industrialized large-scale production.

The invention discloses a detection method of lactoferrin in tears and a dedicated colloidal gold detecting card thereof, and belongs to the field of medical diagnostic reagent technology. The lactoferrin rapid colloidal gold detecting card comprises a detecting card and a colloidal gold test strip, and is prepared by following steps: lactoferrins monoclonal antibodies of high sensitivity and specificity are obtained by taking lactoferrins as antigens to immunize mice; the lactoferrin colloidal gold test strip is obtained by using colloidal gold chromatography; and the colloidal gold test strip is fixed in the detecting card through a groove. The content of lactoferrin in tears is detected by using immune-colloidal gold technology, so that detecting cost is low, and detecting accuracy is high.